Breaking News

Apotex Names President and CEO

August 27, 2014

Desai brings 30 years of pharma experience

Dr. Jeremy B. Desai has been appointed president and chief executive officer of Apotex replacing Jack Kay, who will serve as vice chairman of the board.
 
Dr. Desai has 30 years of pharmaceutical experience having held numerous senior positions. Dr. Desai has been with Apotex for the past 11 years, most recently serving as president and chief operating officer, and executive vice president and global head of R&D.
 
Apotex is among the largest Canadian pharmaceutical companies with more than 5,500 employees in Canada and 10,000 globally. It has exports to 75 countries with planned R&D expenditures of $2.1 billion within the next 10 years.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks